Terminology Service for NFDI4Health
JSON

Brivanib

Go to external page http://purl.obolibrary.org/obo/NCIT_C67040

A pyrrolotriazine-based compound and an inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antineoplastic activity. BMS-540215 specifically targets and binds strongly to human VEGFR-2, a tyrosine kinase receptor and pro-angiogenic growth factor expressed almost exclusively on vascular endothelial cells. Blockade of VEGFR-2 by this agent may lead to an inhibition of VEGF-stimulated endothelial cell migration and proliferation, thereby inhibiting tumor angiogenesis. [ ]

Term info

Label

Brivanib

Synonyms
  • (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol
  • BMS-540215
  • BRIVANIB
  • Brivanib
  • VEGFR2 Inhibitor BMS-540215
  • brivanib
Subsets

NCIT_C63923, NCIT_C128784, NCIT_C157711, NCIT_C157712

ALT DEFINITION

A substance being studied in the treatment of cancer. Brivanib may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of vascular endothelial growth factor receptor 2 inhibitor and a type of antiangiogenesis agent.

CAS Registry

649735-46-6

Chemical Formula

C19H19FN4O3

FDA UNII Code

DDU33B674I

Has Target

http://purl.obolibrary.org/obo/NCIT_C28496

Legacy Concept Name

BMS-540215

Preferred Name

Brivanib

Semantic Type

Pharmacologic Substance

UMLS CUI

C2700604

code

C67040